You are here

PCI Synthesis Submits Patent for Synthesizing Azelaic Acid

NEWBURYPORT, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, submitted a patent filing with the U.S. Patent and Trademark Office (USPTO) for a patent that covers an innovative process to synthesize Azelaic Acid as a drug substance.

Azelaic Acid is used for producing industrial products including polyesters, plasticizers and lubricants and is a component in skin-care products but a large-scale synthesis for drug substance production remains challenging. PCI Synthesis began researching new synthetic processes because it recognized a need for a viable, cost-effective, efficient scale-up process for manufacturing high purity azelaic acid under cGMP conditions for use as an active pharmaceutical ingredient (API).

“Historically, Azelaic Acid was an API derived from an animal-based raw material and not well controlled from a GMP standpoint,” said Ed Price, President of PCI Synthesis. “Current material would not be approvable under the current paradigm of the FDA’s approval process. We have developed a novel multi-step, synthetic route that is manufactured completely under cGMP.  Therefore, our manufacturing process and analytical package meet all the latest FDA requirements for approval as a drug substance for an ANDA.”

About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry.  As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.

Contact:
Linda Pendergast-Savage
Birnbach Communications
508-224-7905
lpendergastsavage@birnbachcom.com

 

Tuesday, January 30, 2018 - 09:15

More Headlines

Zulresso May Alleviate Symptoms for Thousands of Women
Developed for Tumors Resistant to Other TKIs
New Drug Reduces Infection in Chemotherapy Patients
Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV
Unique Bio-Identical Hormone Therapy for Treatment of Hot Flashes
High-Tech “Nightwatch” is Capable of Detecting 85 Percent of Severe Night-Time Epileptic Seizures
Combination of Buprenorphine and Samidorphan Targets Opioid System Safely and Effectively
Prevents Harmful Effects of Chemotherapy